PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6405604

New nitrate delivery systems: buccal nitroglycerin.

J Abrams
View original source ↗Export metadata ↓

Abstract

BN, a new nitrate formulation, has recently been made available. The main advantages of this medication is the combination of prompt onset of action, comparable to that of sublingual NTG, and sustained activity that persists for many hours. The tablet remains pharmacologically effective as long as it remains in the buccal pouch. A variety of studies indicate that BN is well tolerated by patients, acts promptly to provide protection against anginal pain, and has sustained efficacy that persists for 2 to 6 hours. Clinical investigations using serial treadmill testing in patients with angina demonstrate clinical effectiveness and bioactivity of BN beginning within minutes and lasting over 4 hours. The potential advantages of this preparation are discussed, and the formulation is compared to other available longacting nitrates. BN is an effective new addition to the nitrate armamentarium.

Explore related subjects

Angina PectorisCheekHeart FailureHumansNitroglycerinPatient Acceptance of Health CareTabletsTime FactorsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Abrams. 1983. New nitrate delivery systems: buccal nitroglycerin.. https://doi.org/10.1016/0002-8703(83)90251-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

OBJECTIVE: Ischemic preconditioning is an increased tolerance to myocardial ischemia during the second of two consecutive exercise tests. ATP-sensitive K(+) channel blockers, such as glinides and sulfonylurea drugs, can induce loss of ischemic preconditioning. This study aimed to investigate the effects of repaglinide, a hypoglycemic agent with an affinity for myocardial ATP-sensitive K (+)channels, on the results of consecutive exercise tests in patients with diabetes and multivessel coronary artery disease. METHODS: Forty-two patients with type 2 diabetes and chronic stable angina pectoris, and two-vessel or three-vessel disease participated in this study. The patients underwent two consecutive treadmill exercise tests (phase 1). On the day after these exercise tests, 2 mg of oral repaglinide was given to the patients. One week later, two exercise tests were repeated consecutively (phase 2). RESULTS: All patients achieved 1.0-mm ST-segment depression during the four exercise tests (T1, T2, T3, and T4). In phase 2, seven patients improved in time to onset of 1.0-mm ST-segment depression. The worsening of the time to onset of 1.0-mm ST-segment depression in phase 2 demonstrated ischemic preconditioning block in 83.3% of patients (P=0.0001). Even the postexercise electrocardiographic parameters (ST-segment depression morphology and magnitude and arrhythmias) were significantly different between the groups with and without pharmacologic ischemic preconditioning block (P=0.031). CONCLUSIONS: Repaglinide, an oral hypoglycemic agent with ATP-sensitive K(+) channel-blocker activity, eliminated the myocardial ischemic preconditioning in patients with coronary disease and diabetes.

Angina Pectoris↗